1. Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human Macrophages
- Author
-
Yossef Av-Gay, Maria Martinez Hoyos, Ruben Gonzalez Del Rio, Maria Esther Perez Herran, Flavia Sorrentino, Jesus Presa Matilla, Pedro Torres Gomez, Alfonso Mendoza Losana, and Xingji Zheng
- Subjects
0301 basic medicine ,Tuberculosis ,medicine.drug_class ,030106 microbiology ,Green Fluorescent Proteins ,Antitubercular Agents ,Gene Expression ,Microbial Sensitivity Tests ,Antimycobacterial ,Microbiology ,Green fluorescent protein ,Cell Line ,Mycobacterium tuberculosis ,03 medical and health sciences ,Structure-Activity Relationship ,Genes, Reporter ,High-Throughput Screening Assays ,medicine ,Humans ,Pharmacology (medical) ,Luciferase ,Experimental Therapeutics ,Luciferases ,Pharmacology ,biology ,Macrophages ,Hep G2 Cells ,medicine.disease ,biology.organism_classification ,Infectious Diseases ,Cell culture ,Intracellular - Abstract
Here we describe the development and validation of an intracellular high-throughput screening assay for finding new antituberculosis compounds active in human macrophages. The assay consists of a luciferase-based primary identification assay, followed by a green fluorescent protein-based secondary profiling assay. Standard tuberculosis drugs and 158 previously recognized active antimycobacterial compounds were used to evaluate assay robustness. Data show that the assay developed is a short and valuable tool for the discovery of new antimycobacterial compounds.
- Published
- 2015